Drug-eluting stents: long-term safety


Cite item

Full Text

Abstract

The review concerns the problem of late thromboses of drug-eluting stents and their influence on late prognosis of the patients; presents long-term results of the trial of sirolimus-eluting stents implanted to patients with coronary heart disease; analyses mechanisms of development of late stent thrombosis, data from different meta-analyses and registers comparing long-term outcomes in patients with implanted sirolimus-eluting stents and metallic stents; suggests risk factors of late thromboses of drug-eluting stents; presents original evidence on 3.5-year follow-up of patients with implanted sirolimus-eluting stents and metallic stents.

References

  1. Pfisterer M., Brunner-La Rocca H. P., Buser P. T. et al. BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 2006; 48(12): 2584-2589.
  2. Camenzind E., Steg P. G., Wijns W. A meta-analysis of first generation drug eluting stent programs. Circulation 2007; 115: 1440-1445.
  3. Cutlip D. E., Windecker S., Mehran R. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
  4. Nakazawa G., Finn A. V., Virmani R. Drug-eluting stent pathology-should we still be cautious? Nat. Clin. Pract. Cardiovasc. Med. 2008; 5 (1): 1-3.
  5. Awata M., Kotani J., Uematsu M. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007; 116 (8): 910-916.
  6. Togni M., Rдber L., Cocchia R. et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int. J. Cardiol. 2007; 120 (2): 212-220.
  7. Virmani R., Guagliumi G., Farb A. et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705.
  8. Nebeker J. R., Virmani R., Bennett C. L. et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. 2006; 47 (1): 175-181.
  9. Zhang F., Qian J., Ge J. Very late stent thrombosis in late stent malapposition after sirolimus-eluting stent implantation. Int. Heart J. 2007; 48 (5): 591-596.
  10. Steffel J., Latini R. A., Akhmedov A. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005; 112 (13): 2002-2011.
  11. Stone G. W., Moses J. W., Ellis S. G. et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 2007; 356: 998-1008.
  12. Spaulding C., Daemen J., Boersma E. et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 2007; 356: 989-997.
  13. Mauri L., Hsieh W. H., Massaro J. M. et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 2007; 356: 1020.
  14. Nordmann A. J., Briel M., Bucher H. C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J. 2006; 27 (23): 2784-2814.
  15. Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370 (9591): 937-948.
  16. Daemen J., Ong A. T., Stefanini G. G. et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am. J. Cardiol. 2006; 98 (7): 895-901.
  17. de la Torre-Hernдndez J. M., Alfonso F., Hernдndez F. et al. ESTROFA Study Group. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpaсol sobre TROmbosis de stents FArmacoactivos). J. Am. Coll. Cardiol. 2008; 51 (10): 986-990.
  18. Tu J. V., Bowen J., Chiu M. et al. Effectiveness and safety of drug-eluting stents in Ontario. N. Engl. J. Med. 2007; 357 (14): 1393-1402.
  19. Jensen L. O., Maeng M., Kaltoft A. et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J. Am. Coll. Cardiol. 2007; 50 (5): 463-470.
  20. Lagerqvist B., James S. K., Stenestrand U. et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007; 356: 1009-1019.
  21. Williams D. O., Abbott J. D., Kip K. E. DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006; 114 (20): 2154-2162.
  22. Abbott J. D., Voss M. R., Nakamura M. et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J. Am. Coll. Cardiol. 2007; 50 (21): 2029-2036.
  23. Mauri L., Silbaugh T. S., Wolf R. E. et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in massachusetts. Circulation 2008; 118 (18): 1817-1827.
  24. Shishehbor M. H., Goel S. S., Kapadia S. R. et al. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J. Am. Coll. Cardiol. 2008; 52: 1041-1048.
  25. Anstrom K. J., Kong D. F., Shaw L. K. et al. Long-term clinical outcomes following coronary stenting. Arch. Intern. Med. 2008; 168: 1647-1655.
  26. Kirtane A. Oral presentation at the American College of Cardiology (ACC) 2008 Scientific Sessions www.theheart.org

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies